TARGETED THERAPY FOR LUNG CANCER

Patient and Caregiver Guide
TABLE OF CONTENTS

Why Targeted Therapy? ................................................................. 2
Lung Cancer Basics ........................................................................ 2
Changes in Lung Cancer .............................................................. 3
Molecular Testing .......................................................................... 5
Targeted Therapies ...................................................................... 7
  Drugs That Target EGFR ........................................................... 8
  Drugs That Target ALK .............................................................. 8
  Drugs That Target ROS1 ............................................................ 9
  Drugs That Target BRAF .......................................................... 9
  Other Targeted Therapies .......................................................... 9
Things to Know ............................................................................. 11
Clinical Trials ............................................................................ 12
About Lung Cancer Alliance ....................................................... 13

LUNG CANCER ALLIANCE
WHY TARGETED THERAPY?

Until the mid-2000s, treatment choices were mostly limited to surgery, chemotherapy and radiation. Now, people living with lung cancer often have newer, more personalized treatment options.

The goal of targeted therapy is to directly target your unique tumor. This allows treatments to work better and with fewer side effects. This brochure will help you understand targeted therapies and what they mean for you.

LUNG CANCER

Cancer that starts in the lungs – lung cancer – is one of the most common cancers in the United States. But lung cancer is not one disease.

THE BASICS

There are two main types of lung cancer based on how the cancer looks under a microscope:

NON-SMALL CELL LUNG CANCER (NSCLC), the most common type. Two subtypes of NSCLC found most often are:

- Adenocarcinoma
- Squamous Cell Carcinoma

SMALL CELL LUNG CANCER (SCLC), less commonly diagnosed and made up of cells that are smaller in size than most other cancer cells.
CHANGES LEADING TO LUNG CANCER

Research has found drugs called “targeted therapies” that attack cancer cells in new ways. Before we discuss targeted therapies, we will look at how cells work and how they can change into cancer.

Cells are the basic unit in our body. They make up all our organs and structures. Cells have many jobs that are carried out by parts inside the cell. The cell nucleus holds genes that control how the cell works. The genes are carried on chromosomes, 23 from each parent. They are made up of DNA (deoxyribonucleic acid). The genes control what proteins the cell will make. Proteins perform the work of a cell.

There are many ways that normal cells in the lungs change into cancer. You will read and hear terms like mutations, overexpression, fusions, alterations, translocations, deletions and rearrangements and others. These are all types of changes that happen inside cells.

Over time, genes and the proteins they make can change. The changes may happen over generations or over a lifetime due to things to which we are exposed or what we eat and drink. These changes may also happen by random chance. Some changes are helpful. Some do not make a difference one way or the other. But other changes can lead to diseases. Changes causing too much or uncontrolled growth of the cells can lead to cancer.
COMMON GENE AND PROTEIN CHANGES IN LUNG CANCER

Genes are often called by their gene symbol (letters which stand for a longer name). It is helpful to know the name of the changes in your lung cancer. Some changes can be treated with a targeted therapy.

<table>
<thead>
<tr>
<th>SYMBOL</th>
<th>NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR</td>
<td>epidermal growth factor receptor</td>
</tr>
<tr>
<td>ALK</td>
<td>anaplastic lymphoma receptor tyrosine kinase</td>
</tr>
<tr>
<td>ROS1</td>
<td>ROS proto-oncogene 1, receptor tyrosine kinase</td>
</tr>
<tr>
<td>BRAF</td>
<td>B-Raf proto-oncogene, serine/threonine kinase</td>
</tr>
<tr>
<td>PD-L1</td>
<td>Programmed death-ligand 1 (also known as cluster of differentiation 274)</td>
</tr>
<tr>
<td>KRAS</td>
<td>Kirsten rat sarcoma viral oncogene homolog</td>
</tr>
<tr>
<td>MET</td>
<td>MET proto-oncogene, receptor tyrosine kinase</td>
</tr>
<tr>
<td>ERBB2/HER2</td>
<td>erb-b2 receptor tyrosine kinase 2 (also known as human epidermal growth factor receptor 2)</td>
</tr>
<tr>
<td>RET</td>
<td>ret proto-oncogene</td>
</tr>
<tr>
<td>FGFR1</td>
<td>fibroblast growth factor receptor 1</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha</td>
</tr>
<tr>
<td>NTRK1,2,3</td>
<td>neurotrophic receptor tyrosine kinase 1, 2, and 3</td>
</tr>
<tr>
<td>DLL3</td>
<td>delta like ligand 3</td>
</tr>
</tbody>
</table>
MOLECULAR TESTING

WHAT’S THE DIFFERENCE?
To know what kinds of gene and protein changes happened in the cancer, it must be tested. This testing has many names. This brochure uses the terms molecular testing or biomarker testing. These terms cover testing for all the types of changes that can be found in the cancer.

There are changes that are common in each type of lung cancer. If one of these changes is found in the cancer, it is said to have tested “positive.”

Many of the gene changes found in lung cancer only happen in small numbers of people. Right now we do not have therapies to treat all of the gene changes we know about. A lot of research is being done to find treatments to target all of the known changes.

Know your options
New ways to understand and treat lung cancer are being tested and approved more quickly than ever before. Knowing your treatment options makes you an active and empowered member of your team.

If you have not had molecular testing, we can help you get it. Call our treatment specialists at 1-800-298-2436 or visit www.lungmatch.org.

Genetic Testing
Molecular Testing  Mutation Testing
Biomarker Testing
Tumor Testing  Molecular Profiling

Lung MATCH
Lung Cancer Alliance
TESTING DURING DIAGNOSIS AND MONITORING

A tissue biopsy takes tissue from the cancer for testing. Doctors will look at a piece of the biopsy under the microscope. From that, they will know if you have lung cancer and what type. Most molecular testing is also done with tissue biopsy samples. See our brochure Understanding Lung Cancer Biopsies to learn more.

We encourage patients with non-small cell lung cancer (NSCLC) to get their cancer tested at diagnosis. This will make sure you know all the possible treatment choices. If possible, you should have a “panel” test. A panel test checks for many molecular changes at one time rather than just one or two changes. This will use less biopsy tissue than having many single gene tests.

As lung cancer spreads, it can keep changing. Knowing how the cancer changes over time can suggest new treatment choices. So if your cancer comes back, it may be tested again with a new biopsy.

Liquid biopsy is a newer way to do molecular testing. Small amounts of the cancer DNA can be found in your blood or other fluids. Liquid biopsy is when this DNA can be tested instead of DNA from the cancer tissue. Liquid biopsy can be used for molecular testing, but cannot be used for diagnosing cancer or to know what type.

Liquid biopsy works best when the cancer has spread outside of the lung. It may be a good choice if there is not enough tumor tissue to do molecular testing. It may also be a good choice if the cancer needs to be tested again, but a tissue biopsy is not possible. Liquid biopsy is also easier and less risky for the patient.

If you are not sure if your cancer has been tested, ask your health care team. If you have not had testing, ask why not. If you have been tested, talk with your team to make sure you understand the results of your tests.

Testing your cancer helps you know your treatment choices.
TARGETED THERAPIES
Targeted therapies are aimed at a certain “target” in cancer cells. Their goal is stopping the change that is making the cancer grow.

Targeting the change in the cancer can spare the rest of the body from side effects. Chemotherapy kills cells that grow fast. These include cancer cells, but may also include normal cells that grow fast. This is what often causes side effects. Targeted therapies instead attack the differences between normal and cancer cells. They target the changes that are in your cancer. As a result, targeted therapy may have fewer side effects.

The Food and Drug Administration (FDA) approves drugs for use. The FDA has approved targeted therapies for some NSCLC gene changes. These include changes in the genes EGFR, ALK, ROS and BRAF. This booklet describes the FDA approved drugs for changes in each of these genes.

Other types of cancer may have drugs approved to treat other gene changes. Your cancer might have a gene change more common in another cancer type. If so, the doctor may suggest a therapy normally used for that other cancer type.

HOW DO I TAKE A TARGETED THERAPY?
There are two methods to deliver targeted therapies. Some are pills taken by mouth. Others are man-made proteins. These are called monoclonal antibodies. They are given through a vein over several hours in a clinic.

All drugs have two names, a generic name and a brand name. You can tell if a therapy is oral or by vein by looking at the generic drug names.

<table>
<thead>
<tr>
<th>GENERIC DRUG NAMES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Targeted Drugs</strong></td>
</tr>
<tr>
<td>Ends in -ib</td>
</tr>
<tr>
<td>Example: Xalkori’s generic name is crizotinib</td>
</tr>
<tr>
<td>Ends in -mab</td>
</tr>
<tr>
<td>Example: Avastin’s generic name is bevacizumab</td>
</tr>
</tbody>
</table>
### EGFR

<table>
<thead>
<tr>
<th>Drug</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilotrif (afatinib)</td>
<td>Some of the most common changes in NSCLC are changes in the EGFR gene. Gilotrif, Iressa, Tagrisso and Tarceva are oral drugs that can all be prescribed as first treatment. They are used to target many different types of EGFR changes. You should talk with your treatment team about which one of these drugs is best for you. All of them target the most common EGFR changes, but some of the drugs can also target less common changes in the EGFR gene. For example, Gilotrif is approved for the EGFR S768I, L861Q and G719X changes and Tagrisso can target EGFR with the T790M change.</td>
</tr>
<tr>
<td>Iressa (gefitinib)</td>
<td>Portrazza targets EGFR and is given by vein. It is approved for a type of NSCLC called squamous cell. It is given with chemotherapy.</td>
</tr>
<tr>
<td>Tagrisso (osimertinib)</td>
<td></td>
</tr>
<tr>
<td>Tarceva (erlotinib)</td>
<td></td>
</tr>
<tr>
<td>Portrazza (necitumumab)</td>
<td></td>
</tr>
</tbody>
</table>

### ALK

<table>
<thead>
<tr>
<th>Drug</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alecensa (alectinib)</td>
<td>Changes involving the gene ALK can also be found in NSCLC. These oral drugs are approved to treat such “ALK positive” lung cancer when it has spread. Alecensa, Xalkori and Zy kadia are all approved as first treatments. All four of these drugs are approved for use after the cancer has stopped responding to another treatment. This is discussed in the drug resistance section on page 10. Importantly, some of these drugs work to treat cancer in the brain and spinal cord better. Some are better if your cancer has certain changes in ALK. Some may also have fewer side effects. It is important to talk with your healthcare team about which therapy is best for you.</td>
</tr>
<tr>
<td>Alunbrig (brigatinib)</td>
<td></td>
</tr>
<tr>
<td>Xalkori (crizotinib)</td>
<td></td>
</tr>
<tr>
<td>Zy kadia (ceritinib)</td>
<td></td>
</tr>
</tbody>
</table>
## DRUGS THAT TARGET

<table>
<thead>
<tr>
<th>Gene</th>
<th>Drugs</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ROS1</strong></td>
<td>XALKORI (crizotinib)</td>
<td>Changes in the ROS1 gene also occur in NSCLC. Xalkori also targets changes in this gene and is approved for treatment only when the cancer has spread.</td>
</tr>
<tr>
<td><strong>BRAF</strong></td>
<td>TAFLINAR (dabrafenib) WITH MEKINIST (trametinib)</td>
<td>BRAF is another gene that can change in NSCLC. These two oral drugs are approved for NSCLC with a change in BRAF called V600E. The drugs are approved only for cancer that has spread.</td>
</tr>
<tr>
<td><strong>Other Targeted Therapies</strong></td>
<td>AVASTIN (bevacizumab) MVASI (bevacizumab-awwb) CYRAMZA (ramucirumab)</td>
<td>Some targeted therapies work in a different way. These drugs target proteins that cause blood vessel growth. The goal is to “starve” the cancer by cutting off the blood supply that feeds it. Unlike other targeted therapies, these therapies do not need molecular testing. The VEGF protein family causes blood vessel growth around cancers. Avastin targets VEGF-A. It can be taken in combination with chemotherapy. It can be given as a first treatment. It is given by vein. Mvasi is nearly the same therapy as Avastin. It is called a biosimilar. Cyramza targets VEGFR2. It can be used after the cancer has grown during prior treatment. It is given together with chemotherapy. It is given by vein.</td>
</tr>
</tbody>
</table>

Talk to your health care team about molecular testing and if targeted therapy is right for you. For more information, call our treatment specialists at 1-800-298-2436 or visit www.lungmatch.org.
DRUG RESISTANCE

Often targeted therapies work well for some time, but then stop working. This is known as “resistance” to the therapy.

Resistance happens in different ways. There may be new changes in the cancer. When cancer begins to grow again, you may need a new biopsy and molecular testing. This testing looks for causes of resistance. For some types of resistance, there are drugs already approved.

For example, if your cancer is positive for EGFR, you may take Tarceva. It may work well for months or years. Then the drug stops working and the cancer starts to grow again. A common change in EGFR that can cause resistance is called T790M. If testing shows this change happened in your cancer, Tagrisso may be prescribed next.
THINGS TO KNOW

Targeted therapies may have fewer side effects than chemotherapy, but they can sometimes be severe. The most common side effects are rash and diarrhea. Talk with your treatment team about how you might manage them. Other less common side effects may include:

- Vision problems
- Liver problems
- Tiredness
- Nausea
- Heart problems
- Lung problems

For additional information on coping with side effects, visit our website at www.lungcanceralliance.org.

We are still learning how to best use targeted therapies. Studies are underway to use them with other treatments. These other treatments include chemotherapies or immunotherapies. Please see our *Understanding Immunotherapies* brochure for more information on these new treatments. Treatments that include several different types of drugs may become more common in the future.

Targeted drugs can be costly. Drug companies often have programs that may help. We can direct you to the right program. Call our HelpLine at 1-800-298-2436.
CLINICAL TRIALS

Research is moving quickly. There are many clinical trials for different gene changes. When you have your cancer tested, the results may suggest a clinical trial for your gene changes.

A clinical trial is a research study to determine whether a new drug, combination of drugs, procedure or medical device is safe and effective.

There are also new types of clinical trials which test many gene changes at once. They then put you in a part of the trial for your gene changes. Examples are LUNG-MAP and NCI-MATCH. Talk to your treatment team about whether a clinical trial is right for you.

To learn more and find clinical trials near you, call our clinical trial specialists at 1-800-298-2436 or visit www.lungmatch.org.
ABOUT LUNG CANCER ALLIANCE

Lung Cancer Alliance serves and listens to those living with and at risk for lung cancer to reduce stigma, improve quality of life and increase survival. We empower our community by helping people navigate the paths of early detection, diagnosis and treatment. Insights allow us to improve care, amplify awareness, drive advocacy and lead research with the vision of tripling the number of survivors in the next decade.

For more information about our support services, research collaborations, awareness campaigns, advocacy efforts and early detection initiatives, please contact us.

**HELPLINE**
1-800-298-2436

**MOLECULAR TESTING & CLINICAL TRIAL MATCHING**
lungmatch.org

**EMAIL**
support@lungcanceralliance.org

**WEBSITE**
lungcanceralliance.org

**MAIL**
1700 K Street NW, Suite 660
Washington, DC 20006